Physician profile
Andrew Shaw
NPI 1558686915
$4,334.56
in general payments reported to CMS, 2019-2025
45 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $177 · 2021: $65.94 · 2022: $301 · 2023: $476 · 2024: $1,094 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,825 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,824.59 |
| Education | $102.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $368.91 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $339.79 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Janssen Biotech, INC. | $290.80 | 2019-2025 | Tecvayli, Rybrevant, Erleada |
| E.R. Squibb & Sons, L.L.C. | $288.27 | 2019-2025 | Opdivo, Eliquis |
| Celgene Corporation | $278.10 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $264.97 | 2019-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $205.40 | 2021-2025 | Ojjaara, Jemperli |
| Pfizer INC. | $192.86 | 2019-2025 | |
| Eisai INC. | $179.45 | 2019-2025 | |
| Incyte Corporation | $178.35 | 2019-2025 | Jakafi, Niktimvo |
| Genentech USA, INC. | $145.06 | 2019-2025 | Polivy, Tecentriq |
| Astellas Pharma US INC | $134.74 | 2023-2025 | Padcev, Vyloy |
| Lilly USA, LLC | $131.15 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $108.42 | 2024 | Fruzaqla, Alunbrig, Vpriv |
| Regeneron Healthcare Solutions, INC. | $97.18 | 2023-2024 | Libtayo |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.